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BACKGROUND: Interleukin 6 concentration is associated with myocardial injury, heart failure, and mortality after myocardial in-
farction. In the Norwegian tocilizumab non–ST- segment–elevation myocardial infarction trial, the first randomized trial of inter-
leukin 6 blockade in myocardial infarction, concentration of both C- reactive protein and troponin T were reduced in the active 
treatment arm. In this follow- up study, an aptamer- based proteomic approach was employed to discover additional plasma 
proteins modulated by tocilizumab treatment to gain novel insights into the effects of this therapeutic approach.
METHODS AND RESULTS: Plasma from percutaneous coronary intervention–treated patients, 24 in the active intervention and 
24 in the placebo- control arm, drawn 48 hours postrandomization were randomly selected for analysis with the SOMAscan 
assay. Employing slow off- rate aptamers, the relative abundance of 1074 circulating proteins was measured. Proteins identi-
fied as being significantly different between groups were subsequently measured by enzyme immunoassay in the whole trial 
cohort (117 patients) at all time points (days 1–3 [7 time points] and 3 and 6 months). Five proteins identified by the SOMAscan 
assay, and subsequently confirmed by enzyme immunoassay, were significantly altered by tocilizumab administration. The 
acute- phase proteins lipopolysaccharide-binding protein, hepcidin, and insulin- like growth factor- binding protein 4 were all 
reduced during the hospitalization phase, as was the monocyte chemoattractant C-C motif chemokine ligand 23. Proteinase 
3, released primarily from neutrophils, was significantly elevated.
CONCLUSIONS: Employing the SOMAscan aptamer- based proteomics platform, 5 proteins were newly identified that are modu-
lated by interleukin 6 antagonism and may mediate the therapeutic effects of tocilizumab in non–ST-segment–elevation myo-
cardial infarction.
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Interleukin (IL) 6 is a pleotropic cytokine that plays a central role in inflammation. Using the Mendelian ran-domization method, we previously demonstrated that 
IL- 6 has a causal role in coronary artery disease (CAD),1 
findings that have recently been replicated using the 
phenome- wide association approach.2 High circulat-
ing IL- 6 during and immediately after acute myocardial 
infarction (MI) is associated with myocardial injury, heart 
failure, and mortality3 and is a predictor of mortality in 
unstable CAD.4 IL- 6 is therefore considered a potential 
therapeutic target in CAD and MI. Tocilizumab is a hu-
manized anti–IL- 6 receptor antibody that binds to both 
membrane- bound and soluble IL- 6 receptor (sIL- 6R) 
thereby antagonizing IL- 6 signaling.5 It is licensed to 
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treat autoimmune disorders, such as rheumatoid arthri-
tis, but has not yet found use in cardiovascular disease. 
IL- 6 is downstream of IL- 1β. IL- 1β antagonism with the 
monoclonal antibody canakinumab has recently been 
shown to reduce recurrent events and IL- 6 levels in pa-
tients with established CAD in a large phase III clinical 
trial,6 thereby firmly establishing inflammatory cytokines 
as a therapeutic targets in CAD.
An alternative approach to chronic anti- inflammatory 
therapy in patients with CAD is short- term anticytokine 
therapy after MI, which avoids the consequences of 
long- term immunosuppression. The Norwegian tocili-
zumab non–ST- segment–elevation MI (NSTEMI) trial, 
the first human study of IL- 6 blockade in MI,7 was a 
2- center, randomized, double- blind, placebo- controlled 
trial that enrolled 121 patients with NSTEMI. Patients re-
ceived a single intravenous dose of tocilizumab 280 mg 
or placebo before coronary angiography. Multiple blood 
samples were taken during the 3  days postrandom-
ization. The primary end point was a reduction in CRP 
(C- reactive protein), a marker of the acute inflammatory 
response. The trial met its primary end point and also 
demonstrated a reduction in hsTnT (high- sensitivity tro-
ponin T) release (a secondary end point).7 No safety con-
cerns were raised. In this follow- up study using plasma 
samples from the original trial, we employed an aptamer- 
based proteomics approach to discover proteins modu-
lated by the administration of tocilizumab to gain novel 
insights into the action of this drug in this setting.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Patients, Sample Collection, and 
Processing
Stored plasma samples from patients enrolled in 
the Norwegian tocilizumab NSTEMI trial included in 
CLINICAL PERSPECTIVE
What Is New?
• Interleukin 6 antagonism with tocilizumab in 
non–ST-segment–elevation myocardial infarc-
tion reduces troponin T. However, we have hith-
erto been unable to identify cytokines or other 
molecules that could contribute to this effect.
• Employing the powerful SOMAscan proteomics 
platform, we newly identified 5 proteins that are 
modulated by interleukin 6 antagonism in non–
ST-segment–elevation myocardial infarction. 
The acute-phase proteins lipopolysaccharide-
binding protein, hepcidin, and insulin-like growth 
factor-binding protein 4 were all reduced during 
the hospitalization phase, as was the monocyte 
chemoattractant C-C motif chemokine ligand 
23.
• Proteinase 3, released primarily from neutro-
phils, was significantly elevated.
What Are the Clinical Implications?
• These proteins may be secondary downstream 
mediators of the beneficial effect of tocilizumab.
• As the interest in targeting inflammatory cy-
tokines such as interleukin 6 in coronary disease 
grows, proteomics can aid in our understanding 
of the results of this approach and may lead to 
the identification of new targets and more effec-
tive therapeutics.
Nonstandard Abbreviations and Acronyms
ASSAIL-MI  Assessing the Effect of Anti-IL-6 
Treatment in Myocardial Infarction
C5A  complement component C5a 
anaphylatoxin
CAD coronary artery disease
CCL23 CC motif chemokine ligand 23
CRP C-reactive protein
CXCL C-X-C motif chemokine ligand
EIA enzyme immunoassay
HAMP hepcidin antimicrobial peptide
hsTnT high-sensitivity troponin T





NSTEMI  non–ST-segment–elevation 
myocardial infarction
NT-proBNP  N-terminal pro-B-type natriuretic 
peptide
PCI percutaneous coronary intervention
PRTN3 proteinase 3
SerpinA3 serpin family A member 3
sgp130 soluble glycoprotein 130
sIL-6R soluble interleukin 6 receptor
SOMAmers slow off-rate aptamers
UPI UniProt ID
VEGF Vascular endothelial growth factor
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the original trial analyses (117 patients) were used in 
this study. The trial was approved by the Regional 
Committee for Medical and Health Research Ethics 
of South- Eastern Norway and the Norwegian 
Medicines Agency, and conducted according to 
the Declaration of Helsinki. All participants provided 
written, informed consent. Plasma was obtained 
from peripheral venous blood drawn into EDTA 
tubes as previously described.7 For the discovery 
cohort, a total of 48 percutaneous coronary inter-
vention (PCI)–treated patients (24 from the active 
intervention and 24 from the placebo- control arm) 
were selected at random, and plasma from patients 
obtained 48  hours postrandomization (during hos-
pitalization) were analyzed with the commercially 
available SOMAscan assay. These patients were 
selected given that in the original study, a signifi-
cant reduction in hsTnT was only observed in PCI- 
treated patients (71% of the cohort) and the greatest 
difference in CRP between groups was observed 
48 hours postrandomization.7
The SOMAscan assay is a sensitive, high- 
throughput assay employing slow off- rate aptamers 
(SOMAmers) that are single- stranded DNA molecules 
(approximately 40 mer in length) with specific affinity 
for the circulating proteins of interest.8 The “1.3k” assay 
employed measures of a broad range of receptors, ki-
nases, growth factors, and secreted intracellular and 
extracellular proteins.
Samples were processed at the University 
College London with quality- control oversight from 
SomaLogic. Methods are described elsewhere.8 
Briefly, the plasma was incubated with a mixture of 
biotin- labeled SOMAmers, followed by capture of all 
SOMAmer- protein complexes on streptavidin beads. 
After further processing, a mixture of free SOMAmers 
is produced that quantitatively reflects the protein 
concentrations in the original sample. The SOMAmers 
are subsequently hybridized to DNA oligonucleotides 
on an array. The assay signal is expressed as relative 
fluorescence units. SomaLogic also performs nor-
malization to reduce intrasample bias and calibration 
procedures to decrease between- sample variability. 
After all quality- control procedures were completed, 
the relative abundance of 1074 proteins were avail-
able for each sample.
Transformation of SOMAscan Data
To enable statistical analysis, the distribution of rela-
tive fluorescence unit values was normalized by taking 
the natural log. This transformation was selected as 
it resulted in the greatest reduction in outliers, skew-
ness, and kurtosis, and aided interpretability as com-
pared with other transformations under consideration 
(Figure S1).
SOMAscan Validation
To assess the validity of the SOMAscan assay, the con-
centration of IL- 6, sIL- 6R, sgp130 (soluble glycoprotein 
130), and CRP measured by other means in the placebo 
group of the original study were compared with measure-
ments obtained using SOMAscan. The methods used for 
measurement of these proteins in the original study are 
described elsewhere.7 The linear correlation between 
these 4 analytes was assessed with Pearson correlation.
Protein Discovery Using SOMAscan
Independent samples t tests were performed to as-
sess the mean differences in protein measurements 
between patients randomized to the tocilizumab and 
placebo groups. Post hoc correction for multiple com-
parisons was performed with Bonferroni test and the 
Benjamini- Hochberg procedure with false discovery 
rate set to 0.1. The more liberal of these approaches 
(Benjamini- Hochberg) was selected given the explora-
tory nature of the study.
Temporal Profile of Discovered Proteins 
Over the Entire Time Course
To corroborate findings from the SOMAscan platform 
and to understand the full temporal profile of the pro-
teins that were modulated by tocilizumab, these pro-
teins were measured in the Norwegian tocilizumab 
NSTEMI trial cohort (tocilizumab n=58, placebo 
n=59) over the entire time course of the study. During 
the trial, blood samples were drawn prerandomiza-
tion and at 6 time points after the administration of 
drug or placebo during the first 56 hours of hospitali-
zation (day 1: evening; day 2: morning, afternoon, and 
evening; and day 3: morning and afternoon). Further 
samples were drawn at 3 and 6  months postrand-
omization. Plasma was stored in aliquots at −80°C 
until analyzed. The proteins were measured by en-
zyme immunoassay (EIA) using commercially avail-
able antibodies (Table S1). A commercially available 
CCL23 (C- C motif chemokine ligand 23) antibody was 
employed in the EIA, which recognizes both CCL23 
and the splice variant Ck- beta- 8- 1, therefore only 1 
measure, encompassing both of these proteins, was 
made. All proteins were analyzed in duplicate in a 
384- well format using a combination of a SELMA pi-
petting robot (Analytik Jena AG) and a BioTek (BioTek 
Instruments, Inc) dispenser/washer. Absorption was 
read at 450  nm with wavelength correction set to 
540 nm using an ELISA plate reader (BioTek). Intra- 
assay and interassay coefficients were <10%.
Statistical Analysis 
The effects of tocilizumab treatment on circulating lev-
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presence of a significant tocilizumab*time interaction 
with an ANOVA test using a mixed model with patient 
(intercept) as a random effect, while adjusting the 
fixed effects of tocilizumab treatment, time, and their 
interaction with baseline covariates. For these analy-
ses, log- transformed values for all biomarkers were 
used to achieve normalization/near- normalization of 
distributions, and data are expressed as the back- 
transformed estimated marginal mean with 95% CIs. 
As well as analyzing the whole cohort, a subanaly-
sis of patients treated with PCI versus untreated was 
also performed.
Interaction Analysis
To give further insight, the association between 
significantly regulated proteins and key variables 
measured in the original study was assessed. These 
variables include CRP, hsTnT, NT- proBNP (N-terminal 
pro- B- type natriuretic peptide), IL- 6, and neutro-
phils. Log- transformed area under the curve values 
of each analyte during the acute phase (days 1–3) 
was used to assess associations. If no interaction 
with tocilizumab treatment was detected, Pearson 
regression coefficient for the whole population was 
reported. If an interaction with tocilizumab was pre-
sent, Pearson regression coefficient within each 
group was reported.
Functional Enrichment Analysis
In order to understand how the proteins modified by 
tocilizumab correlate with its wider effects on the pro-
teome, we performed a functional enrichment analy-
sis. This involved comparing the list of proteins altered 
by tocilizumab with an uncorrected P value <0.05 
(Table  S2), excluding IL- 6 and sIL- 6R as they are di-
rectly modulated by tocilizumab, and SerpinA3 (serpin 
family A member 3) (discordant data from SOMAscan 
and EIA), to the list of 1054 proteins measured by the 
SOMAscan assay using WebGestalt (WEB- based 
Gene Set Analysis Toolkit).9 The analysis used Gene 
Ontology annotation and ontology files data10 ac-
cessed on January 14, 2019. We set WebGestalt to 
report the top 100 enriched biological processes and 
then applied the affinity propagation function to gen-
erate the final list. Biological processes that were not 
relevant, eg, “regulation of symbiosis,” were excluded. 
Given the exploratory nature of this analysis, a false- 
discovery rate threshold was not set and enrichment 
was considered significant with P<0.05.
RESULTS
The 48 patients whose samples were included in the 
SOMAscan analysis did not differ significantly from the 
overall cohort, neither were there any differences be-
tween the study groups (Table  1). The mean age of 
the cohort was 56.8 years, 42 (87.5%) were men, 12 
(25%) had diabetes mellitus, 22 (45.8%) were current 
smokers, and mean body mass index was 30.4 kg/m2. 
Blood pressure at baseline was 138/83 mm Hg.
SOMAscan Validation
Correlations between the SOMAscan values and the 
equivalent measurements from the original study were 
IL- 6 (r=0.52 P=0.008), sIL- 6R (r=0.54 P=0.006), sgp130 
(r=0.49, P=0.02), and CRP (r=0.93, P<0.001).
Protein Discovery Using SOMAscan
In the discovery cohort, 11 proteins were found to be 
significantly different between the tocilizumab and 
placebo groups using the SOMAscan assay (0.1 false 
discovery rate threshold of P=0.0005612) (Table  2, 
Table 1. Patient Demographics According to Treatment Group Between the Original Study and the Subset Used for the 
SOMAscan Assay
Discovery Population, N=48 Original Study, N=117
Placebo, n=24 Active, n=24 Placebo, n=59 Active, n=58
Risk factors baseline
Age, mean (SD), y 56.1 (10.2) 57.4 (7.2) 60.1 (9.9) 59.8 (7.7)
Women, No. (%) 3 (12.5) 3 (12.5) 5 (8.5) 9 (15.5)
Body mass index, mean 
(SD), kg/m2
30.5 (4.8) 30.3 (3.4) 27.4 (4.4) 28.8 (3.3)
Diabetes mellitus, No. (%) 7 (29.2) 5 (20.8) 10 (16.9) 11 (19.0)
Current smoking, No. (%) 10 (41.7) 12 (50) 17 (28.8) 15 (26.3)
PCI- treated 24 (100) 24 (100) 47 (80) 41 (71)
Systolic BP, mm Hg, mean 
(SD)
137.7 (16.7) 139.5 (21.7) 136.8 (18.0) 139.7 (18.1)
Diastolic BP, mm Hg, mean 
(SD)
81.7 (12.1) 84.8 (12.0) 80.5 (12.1) 82.9 (12.0)
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Figure  1). Two of the identified proteins were sIL- 6R 
(UniProt ID [UPI]: P08887) and IL- 6 (UPI: P05231), both 
of which had been shown to be increased by the admin-
istration of tocilizumab in the original study. Therefore, 
the findings for 9 of the identified proteins were novel. 
Of these, 2 were increased by the administration of to-
cilizumab. These were alpha- 1- antichymotrypsin com-
plex (also termed SerpinA3 [serpin family A member 
3]; UPI: P01011) and myeloblastin (also termed PRTN3 
[proteinase 3]; UPI: 24158).
Seven proteins were decreased in the tocilizumab 
group as compared with the placebo group including 
the acute- phase proteins HAMP (hepcidin antimicro-
bial peptide) (UPI: P81172), IGFBP4 (insulin- like growth 
factor- binding protein 4) (UPI: P22692), and LBP 
(lipopolysaccharide- binding protein) (UPI: P18428), as 
well as VEGFA (vascular endothelial growth factor A) 
(UPI: P15692), C5A (complement component C5a ana-
phylatoxin) (UPI: P01031), and both the CCL23 (UPI: 
P55773) and its splice variant Ck- beta- 8- 1. Table  S2 
lists all proteins whose relative abundance differed be-
tween groups with an uncorrected P value <0.05.
Temporal Profile of Discovered Proteins 
Over the Entire Time Course Measured by 
EIA
Over the first 56 hours of serial samples during hospi-
talization, 6 of the 8 proteins (Ck- beta- 8- 1 included in 
the CCL23 EIA) were found to have significant differ-
ences in concentration between the tocilizumab and 
placebo groups when assessed by EIA (Figure 2). LBP, 
HAMP, and IGFBP4, as well as CCL23, were reduced 
throughout, in agreement with the SOMAscan assay. A 
total of 41 of the 58 patients (70.7%) in the tocilizumab 
group underwent PCI, and subanalysis showed that 
the reductions in LBP, IGFBP4, and CCL23 were only 
present in this group (Figure 2).
As found with the SOMAscan assay, tocilizumab in-
duced a rapid increase in PRTN3 that was sustained 
for 56 hours, compared with no changes in the pla-
cebo group (Figure 2). This effect was seen regardless 
of whether the patients underwent PCI (Figure 2).
In contrast to the proteomic data, however, the 
concentration of SerpinA3 as measured by EIA was 
decreased, rather than elevated, and there was no sig-
nificant difference in the concentrations of VEGFA or 
C5A levels between the groups (Figure 2). Levels of all 
examined proteins were similar in the 2 groups at the 2 
long- term follow- up time points (3 and 6 months).
Associations of Discovered Proteins With 
Key Variables
There were significant positive, but relatively mod-
est, correlations found between CRP, hsTnT and NT- 
proBNP and LBP, HAMP, and IGFBP4; however, there 
was no effect of tocilizumab on these associations 
(Figure  3). In contrast, there was an association be-
tween CRP and PRTN3 in the placebo group, which 
was lost in the tocilizumab group. CCL23 was not as-
sociated with any of the variables, and PRTN3 was 
not associated with the myocardial markers hsTnT and 
NT- proBNP.
Whereas IL- 6 was positively correlated with PRTN3, 
it was negatively correlated with HAMP, with the same 
pattern in both the placebo and tocilizumab groups 
(Figure 3). In contrast, a significant positive correlation 
between IL- 6 and CCL23 was lost in the tocilizumab 
group.
The strongest correlations were found with neu-
trophil numbers. Circulating neutrophil concentrations 
Table 2. Significant Proteins Identified by the SOMAscan Assay, Ordered by P Value
Protein (SOMAscan 
Name)








IL- 6 receptor subunit α 1.25 (0.08) 2.31E- 20 1.09 1.41 3.05E- 17 2.4809E- 17
α1- Antichymotrypsin 
complex/SerpinA3
0.36 (0.06) 3.25E- 07 0.24 0.47 0.0004 0.0002
Hepcidin −0.68 (0.13) 2.41E- 06 −0.94 −0.43 0.0032 0.0009
IGFBP4 −0.22 (0.05) 2.71E- 05 −0.32 −0.13 0.0357 0.0073
Myeloblastin/PRTN3 0.65 (0.14) 3.76E- 05 0.36 0.95 0.0496 0.0081
VEGFA −0.20 (0.04) 4.13E- 05 −0.29 −0.11 0.0544 0.0074
IL- 6 0.81 (0.18) 4.82E- 05 0.45 1.18 0.0635 0.0074
Ck- beta- 8- 1 −0.36 (0.08) 5.00E- 05 −0.53 −0.20 0.0658 0.0067
CCL23 −0.28 (0.07) 0.0003 −0.42 −0.14 0.3448 0.0312
C5A −0.29 (0.07) 0.0004 −0.44 −0.14 0.4950 0.0404
LBP −0.23 (0.06) 0.0006 −0.35 −0.10 0.7392 0.0548
Benjamini- Hochberg false discovery rate set to 0.1. C5A indicates complement component C5a anaphylatoxin; CCL23, C- C motif chemokine ligand 23; 
IGFBP4, insulin- like growth factor- binding protein 4; IL, interleukin; LBP, lipopolysaccharide- binding protein; PRTN3 proteinase 3; SerpinA3, serpin family A 
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were positively correlated with the 3 acute- phase pro-
teins (LBP, HAMP, and IGFBP4) in the placebo groups 
(Figure  3). However, in the case of LBP and HAMP, 
this association was lost in the tocilizumab group. 
Interestingly, a significant positive correlation in the 
placebo group between neutrophils and PRTN3 was 
inversed in the tocilizumab group.
As LBP has been shown to be associated with 
high- density lipoprotein cholesterol levels11 and tocili-
zumab has been shown to have a pronounced effect 
on lipids and in particular triglycerides,12 we evaluated 
associations between LBP and high- density lipopro-
tein cholesterol. First, we did not observe an effect 
of tocilizumab on triglycerides (area under the curve 
median 4.97 versus 5.00 mmol/L, versus placebo, re-
spectively; P=0.80). Second, no correlation between 
the area under the curves of LBP and high- density li-
poprotein cholesterol in the whole population (r=–0.09, 
P=0.34) at any individual time point (all P>0.2) or for 
change from baseline to 48 hours postrandomization 
(r=0.11, P=0.25) was observed. Evaluating these cor-
relations within groups, ie, placebo versus tocilizumab 
or PCI versus non- PCI, revealed similar results.
Functional Enrichment Analysis
Employing WebGestalt we identified of 17 biological 
processes enriched by tocilizumab (Table 3). Of these 
enriched processes, notable ones including at least 1 
Figure 1. Difference in relative abundance of the 1074 SOMAscan proteins between the placebo and tocilizumab groups. 
Shown on the 
x axis is the log- relative fluorescence unit (RFU) difference between groups, and on the y axis is the −log P value. Named proteins 
(in green) are those surpassing the false discovery rate (FDR) of 0.1 (Benjamini- Hochberg). The Bonferroni threshold is also shown. 
The slow off-rate aptamer name is used. Soluble interleukin 6 (IL-6) receptor is beyond the axis used (P=2.3×10−20). C5A indicates 
complement component 5a anaphylatoxin; IGFBP4, insulin- like growth factor- binding protein 4; LBP, lipopolysaccharide- binding 
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Figure 2. Plasma concentrations of proteins discovered by SOMAscan measured by enzyme immunoassay in the whole 
study cohort over time.
Plasma levels of LBP (lipopolysaccharide- binding protein), CCL23 (C- C motif ligand 23) (cross- reacts with Ck- beta- 8- 1), HAMP 
(hepcidin antimicrobial peptide), IGFBP4 (insulin- like growth factor- binding 4), PRTN3 (proteinase 3), SerpinA3 (serpin family A member 
3), VEGF (vascular endothelial growth factor A), and C5A (complement component 5a anaphylatoxin) during hospitalization (baseline 
to 3 days) and follow- up (3 and 6 months) in patients with non–ST- segment–elevation myocardial infarction receiving placebo (n=59) 
or tocilizumab (n=58) and analyzed according to whether the patient did (n=88) or did not (n=29) undergo percutaneous coronary 
intervention (PCI) (n=88). Circles and bars represent estimated marginal means and 95% CIs normalized for baseline values. The P 
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of the 5 novel proteins we had identified were those re-
lated to acute inflammation such as response to tumor 
necrosis factor (CCL23, HAMP), cell chemotaxis (LBP, 
CCL23), and granulocyte migration (LBP, CCL23, 
PR3), as well as cardiac muscle development (HAMP).
DISCUSSION
Employing an aptamer- based proteomics approach 
on samples from the Norwegian tocilizumab NSTEMI 
trial cohort together with EIA measurements of these 
proteins across all time points, we have identified 5 
proteins that are modulated by the administration of 
tocilizumab in NSTEMI. These results have revealed 
several interesting insights into the effects of tocili-
zumab treatment in NSTEMI and raised some impor-
tant questions.
Acute- Phase Proteins: LPB, HAMP, 
IGFBP4—Potential Secondary Mediators 
of IL- 6 Inhibition During NSTEMI
MI is associated with an acute- phase response, driven 
largely by IL- 6 signaling.13 Thus, we have recently dem-
onstrated that IL- 6 blockade markedly lowers CRP 
in NSTEMI.7 Given this, it is not surprising that the 
SOMAscan assay identified other acute- phase pro-
teins (LBP, HAMP, and IGFBP4), which were lower in 
the tocilizumab treatment group and were positively 
correlated with CRP. Furthermore, while a positive 
correlation was detected between LBP and HAMP 
and neutrophil numbers in the placebo group, this 
association was not present in patients treated with 
tocilizumab, which suggests that the decline in these 
markers could be directly linked to the neutropenia 
observed during anti–IL- 6 therapy. Nonetheless, apart 
Figure  3. Associations between newly identified proteins modulated by tocilizumab and 
parameters measured in the original study.
Dotplots showing associations between area under the curve (log- transformed) of plasma levels of 
LBP (lipopolysaccharide- binding protein), CCL23 (C- C motif ligand 23), hepcidin, IGFBP4 (insulin- like 
growth factor- binding 4), and PRTN3 (proteinase 3) with CRP (C- reactive protein), hsTnT (high- sensitivity 
troponin T), NT- proBNP (N-terminal pro-B-type natriuretic peptide), interleukin 6 (IL- 6), and neutrophil 
counts during hospitalization (baseline to 3 days) in patients with non–ST- segment–elevation myocardial 
infarction receiving placebo (red circles, n=59) or tocilizumab (blue circles n=58). Black lines represent 
the regression line and the numbers in the bottom right the correlation coefficient for the whole group. If 
an interaction with tocilizumab was detected (green frames, see Statistical Analysis), the regression lines 
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from reflecting an attenuating effect of IL- 6 antagonism 
on the acute- phase response, the downregulation of 
these molecules could also have a direct physiological 
impact.
HAMP is a key regulator of iron homeostasis and 
has recently been shown to be produced within the 
myocardium post- MI by both macrophages14 and 
cardiomyocytes.15 IL- 6 has also been shown to in-
duce monocyte gene expression of HAMP14 and 
may be responsible for its production in myocytes.15 
Interestingly, in the functional analysis, HAMP clus-
tered with other proteins involved in cardiac muscle 
development, and indeed there is increasing evi-
dence that HAMP plays a central role in controlling 
myocyte iron and oxygen redox status and thus 
maintaining normal metabolism.16 Given this, its re-
duction post- MI may impact the ability of infarcted 
myocardium to control oxygen free radicals produced 




Ratio P Value N n Proteins
Erythrocyte homeostasis 5.325 0.00051983 20 6 JAK2, EPO, GPI, VEGFA, TGFBR3, MAPK14
Cellular response to chemical 
stimulus
1.4005 0.00073273 545 43 Not listed given large number. Includes 
CCL23, LBP, PR3, HAMP
Response to TNF 2.5927 0.00079303 89 13 CCL23, HAMP, CCL24, JAK2, LTA, CXCL8, 
TNFRSF1A, TNFSF8, LTB, MAPK14, 
CCL4L1, CPNE1, CXCL16
Cell chemotaxis 2.2756 0.0012316 117 15 CCL23, LBP, CCL24, FGF18, C5, S100A9, 
PDGFR8, CXCL8, VEGFA, AZU1, IL- 16, 
MAPK14, CCL4L1, CXCL16, IL- 37
Cardiac muscle tissue 
development
3.4634 0.0013910 41 8 HAMP, PDGFRB, VEGFA, BMPR1A, 
MAP2K4, FHF8, TGFBR3, MAPK14
Induction of positive 
chemotaxis
7.1 0.0014841 10 4 CXCL8, VEGFA, AZU1, IL- 16
Coronary vasculature 
morphogenesis
10.65 0.0015702 5 3 PDGFRB, VEGFA, TGFBR3
Cardiac muscle cell 
development
6.4545 0.0022344 11 4 HAMP, PDGFRB, VEGFA, MAP2K4
Positive regulation of organ 
growth
4.9306 0.0023334 18 5 HAMP, BMPR1A, FGF8, TGFBR3, MAPK14
Monocyte differentiation 6.6563 0.0077796 8 3 APCS, CSF1R, VEGFA
Positive regulation of 
macromolecule biosynthetic 
process
1.7364 0.0088122 184 18 LBP, JAK2, EPO, PDGFRB, H2AFZ, VEGFA, 
TNFRSF1A, AZU1, CCNA2, CDK2, TNFSF8, 
BMPR1A, MAP2K4, LTB, CAMK1, MAPK14, 
HJV, IL- 17F
Positive regulation of tyrosine 
phosphorylation of STAT 
protein
2.8239 0.0093213 44 7 JAK2, CRLF1, EPO, CSF1R, VEGFA, 
TNFRSF1A, CLCF1
Granulocyte migration 2.3843 0.0099917 67 9 CCL23, LBP, PRTN3, CCL24, S100A9, 
CXCL8, MAPK14, CCL4L1, IL37
Aorta morphogenesis 5.9167 0.011205 9 3 PDGFRB, BMPR1A, FGF8
Regulation of nitrogen 
compound metabolic process
1.2723 0.012931 572 41 Not listed given large number. Includes 
CCL23, LBP, PRTN3, HAMP, IGFBP4
Cell migration 1.4604 0.014433 316 26 Not listed given large number. Includes 
CCL23, LBP, PRTN3
Negative regulation of neuron 
death
2.485 0.018581 50 7 JAK2, CRLF1, EPO, GPI, MAP2K4, FGF8, 
CLCF1
Seventeen gene ontology biological processes were identified as enriched in the blood in patients following tocilizumab treatment. AZU1 indicates azurocidin 
1; BMPR1A, bone morphogenetic protein receptor 1A; BMPR1A, bone morphogenic protein receptor type 1A; CAMK1, calcium/calmodulin- dependent protein 
kinase 1; CCL23, C- C motif chemokine ligand 23; CCL24, C- C motif chemokine ligand 24; CCL4L1, C- C motif chemokine ligand 4- like 1; CCNA2, cyclin 
A2; CDK2, cyclin- dependent kinase 2; CLCF1, cardiotropin- like cytokine factor 1; CRLF1, cytokine receptor- like factor 1; CSF1R, colony- stimulating factor 
1 receptor; CXCL8, C- X- C motif chemokine ligand 8; EPO, erythropoietin; FGF8, fibroblast growth factor 8; GPI, glycosylphosphatidylinositol; H2AFZ, H2A 
histone family, member Z; HAMP, hepcidin antimicrobial peptide; HJV, hemojuvelin; IGFBP4, insulin- like growth factor- binding protein 4; IL17F, interleukin 17F; 
IL37, interleukin 37;JAK2, Janus kinase 2; LBP, lipopolysaccharide- binding protein; LTB, lymphotoxin β; MAP2K4, mitogen- activated protein kinase 4; MAPK14, 
mitogen- activated protein kinase 14; N, number of proteins associated with gene ontology term in SOMAscan assay data set; n, number of proteins associated 
with gene ontology term in SOMAscan assay data set and the query list of differentially expressed proteins identified following tocilizumab treatment; PDGFRB, 
platelet- derived growth factor receptor β; PRTN3, proteinase 3; S100A9, S100 calcium- binding protein A9; TNFRSF1A, tumor necrosis factor receptor super 
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by iron overload.17 However, conversely, HAMP has 
also been shown to contribute to plaque destabili-
zation via activation of macrophages,18 and therefore 
there may also be advantages to its downregulation 
post- MI.
LBP, which plays a key role in the immune re-
sponse to gram- negative bacteria, has also recently 
been identified as a novel component of atheroscle-
rotic plaques that is released into the circulation after 
plaque rupture19 and is associated with increased car-
diovascular risk.20 LBP has been shown to closely as-
sociate with high- density lipoprotein cholesterol11 and 
tocilizumab has pronounced effects on lipids,12 but we 
were unable to demonstrate any associations between 
tocilizumab, LBP, and lipids. In the functional analysis, 
LBP was associated with multiple enriched biological 
processes including cell and granulocyte chemotaxis/
migration, suggesting that it may have a significant role 
in mediating inflammation post- MI. Indeed, it has been 
suggested that LBP may have a direct role in myocar-
dial inflammation post- MI via CD14/Toll- like receptor 
4–associated pathways.19
IGFBP4, a binding protein that prolongs the half- 
life of insulin- like growth factor, may also play a role in 
acute MI. Insulin- like growth factor stimulation of mac-
rophages results in inflammatory cytokine release21 
and it has also been shown to play a role in plaque 
development.22
Therefore, given the evidence from the functional 
analysis and emerging literature, it is possible that the 
reduction in the 3 identified acute- phase proteins may 
contribute to the anti- inflammatory effects of IL- 6 inhi-
bition in NSTEMI.
CCL23: a Monocyte Chemoattractant 
That Could Contribute to the  
Anti- Inflammatory Effect of Tocilizumab  
in NSTEMI
CCL23 is a member of the CC chemokine family and 
is involved in leukocyte trafficking and activation. For 
example, it has been shown to act as both a monocyte 
chemoattractant and to stimulate the release of mono-
cyte chemoattractant protein- 1 and tumor necrosis 
factor α from these cells.23 A specific role for CCL23 
in ischemic heart disease is supported by increased 
expression in atherosclerotic lesions and in the circula-
tion in patients with atherosclerosis,23 and by its as-
sociation with cardiovascular outcomes.20 However, its 
role in MI has not previously been studied and this is 
the first study to our knowledge to suggest a direct link 
between IL- 6 signaling and CCL23. Given that mono-
cytes play a key role in the inflammatory response dur-
ing plaque destabilization and post- MI maladaptive 
remodeling,24 the suppression of CCL23 may be a key 
mechanism by which tocilizumab beneficially modifies 
the inflammatory milieu post- MI and warrants further 
investigation.
However, although CCL23 was associated with 
several enriched biological processes related to in-
flammation, including response to tumor necrosis 
factor, cell chemotaxis/cell migration, and granulocyte 
migration, IL- 6 inhibition had a variable effect on pro-
teins associated with these processes. For example, 
with regards to cell chemotaxis (Table  S3), certain 
proteins were downregulated in the same manner as 
CCL23, including the cytokine IL- 37 and chemokine 
CXCL (C- X- C motif chemokine ligand) 16. However, 
others were elevated, such as the cytokine/chemo-
kines CXCL8, CCL24, CCL4L1, and IL- 16. Given this, 
tocilizumab likely has pleiotropic effects on chemotaxis 
post- MI and the overall net effect on cell trafficking is 
therefore difficult to discern.
PRTN3 is Related to Neutropenia During 
Tocilizumab Therapy in NSTEMI
A major finding in our study was the marked and early 
increase in PRTN3 during IL- 6 inhibition. PRTN3 is a 
serine protease mainly expressed by neutrophils, but 
may also be expressed by endothelial cells.25 The as-
sociated proteases myeloperoxidase and azurocidin 
are also elevated in the SOMAscan assay but did not 
reach the multiplicity adjusted threshold of significance 
(Table  S2). Although the mechanism for tocilizumab- 
induced neutropenia is not firmly established, it may 
occur rapidly within few hours, indicating limited in-
volvement of bone marrow.26 In patients with rheuma-
toid arthritis, the neutropenia induced by tocilizumab 
has been attributed to the inhibition of antiapoptotic 
actions of IL- 6 on activated neutrophils,27 and evidence 
for a proapoptotic effect of tocilizumab treatment has 
been demonstrated in vitro.28 Thus, the rapid increase 
in PRTN3 could be related to its release from apoptotic 
neutrophils. This is supported by the interaction analy-
sis, which revealed that while neutrophils and PRTN3 
were positively correlated in the placebo group, they 
were negatively correlated in the tocilizumab group. In 
addition, PRTN3 itself may also directly stimulate neu-
trophil apoptosis,29 which may further increase PRTN3 
release. As neutrophil apoptosis is a key process in 
the resolution of inflammation, we speculate that the 
proapoptotic effects of PRTN3 on neutrophils could 
contribute to the beneficial effects of tocilizumab fol-
lowing MI.
As with other neutrophil serine proteases, how-
ever, there are also many potential deleterious effects 
associated with its release in the context of MI.30,31 
Furthermore, antibodies against PRTN3 and myelop-
eroxidase are associated with antineutrophil cytoplas-
mic antibody–related vasculitis.32 Thus, this important 




 http://ahajournals.org by on February 2, 2021
J Am Heart Assoc. 2020;9:e015628. DOI: 10.1161/JAHA.119.015628 11
George et al Proteomic Analysis of  IL - 6 Antagonism in  NSTEMI 
order to establish the underlying mechanism and to 
understand whether the increased levels of PRTN3 
may augment or mitigate the beneficial effects of IL- 6 
inhibition in NSTEMI. From a clinical perspective, it 
would also be important to assess whether there is an 
increased risk of developing antineutrophil cytoplasmic 
antibody autoantibodies in patients who receive tocili-
zumab in the context of MI.
Is IL- 6 Antagonism Only Likely to Be of 
Benefit in Patients With Reperfused MI?
In the Norwegian tocilizumab NSTEMI trial, the area 
under the curve for hsTnT during hospitalization was 
significantly lower in the tocilizumab arm (159 versus 
234 ng/L per h, P=0.07); however, subanalysis of the 
study demonstrated that this reduction was only ob-
served in the group of patients who underwent PCI.7 
Similarly, in this follow- up study, the reductions in 
LBP, IGFBP4, and CCL23 were also only observed 
in the group that underwent PCI. These data suggest 
that IL- 6 antagonism may have more significant anti- 
inflammatory and therapeutic effects in the setting of 
reperfusion. This is possibly because reperfusion is 
associated with a substantially more robust inflamma-
tory response compared with ischemia alone,33 char-
acterized by both increased myocardial IL- 6 mRNA 
transcription34 and plasma concentrations.35 The 
ASSAIL- MI (Assessing the Effect of Anti- IL- 6 Treatment 
in Myocardial Infarction) trial,36 which has enrolled pa-
tients with ST- segment–elevation MI undergoing pri-
mary PCI, will help determine whether targeting IL- 6 in 
the context of early reperfusion is likely to be of thera-
peutic benefit.
Study Strengths and Limitations 
Our study has several strengths including the applica-
tion of a proteomics platform with over 1000 analytes, 
corroboration of the assay with proteins measured in 
the original study, and verification of SOMAscan find-
ings by EIA across the whole time course. However, 
there are some notable limitations and caveats.
Although significant, the correlation between EIA 
and SOMAscan measures of IL- 6, sIL- 6R, and sgp130 
were relatively weak (r=0.49–0.52), whereas the correla-
tion between measures of CRP were strong (r=0.93). 
This may reflect the accuracy and sensitivity of assays 
used for these analytes in the original study. Whereas 
CRP was the primary outcome and measured with a 
high- sensitivity, automated, clinical- grade immunotur-
bidimetric assay (Roche Diagnostics) with a within- run 
coefficient of variance of ≈1.5% and between- run co-
efficient of variance of 2.5%37 the other assays were 
research- grade EIAs (R&D Systems), which are less 
accurate and have higher within- and between- run co-
efficient of variance values of up to 10%.38
Furthermore, although 8 of the 11 proteins that 
were identified by the SOMAscan proteomics plat-
form were confirmed to be significantly altered by 
tocilizumab over the entire study time course by EIA, 
this was not the case for SerpinA3, VEGFA, and C5A. 
This may be attributable to the time point selected 
for SOMAscan not being reflective of the entire time 
course, technical variability in the assays employed, 
or biological instability of some of the measured 
analytes.39
We only performed the initial SOMAscan assay on 
samples from 48 patients (24 tocilizumab, 24 controls) 
at a single time point. Given the small sample size, 
and the liberal adjustment for multiplicity that was se-
lected (Benjamini- Hochberg with a false discovery rate 
set to 0.1), there is a chance that we selected false- 
positive proteins for further study. Conversely, given 
the small sample size, there may be several important 
false- negative proteins within this group that are sig-
nificantly regulated by IL- 6, and increasing the num-
ber of samples would have given us greater power to 
identify them. Furthermore, the use of samples from 
the patients who underwent PCI for the initial proteom-
ics may have biased the discovery of proteins towards 
those that are only modulated in this context. The 
list of 50 proteins that were different between the 2 
groups with an uncorrected P value <0.05 is included 
in Table S2. Our study did not have any hard outcome 
measures and we are not proposing that any of the 
markers represent prognostic biomarkers in NSTEMI.
Finally, to perform the network analysis using 
WebGestalt, we included all of the proteins, which were 
significantly altered by tocilizumab, including those that 
were not significant after adjustment for multiplicity. 
Furthermore, these proteins were not subsequently 
measured in the whole cohort by EIA. Therefore, the 
results of the network analysis must be considered 
complementary and hypothesis- generating and fur-
ther work is required to understand the effects of IL- 6 
inhibition on the wider proteome post- MI.
CONCLUSIONS
We have hitherto been unable to identify cytokines or 
other molecules that could contribute to the benefit of 
tocilizumab in our NSTEMI study.40,41 Herein, however, 
by employing a powerful, aptamer- based proteomics 
platform, we have identified several proteins that are 
significantly modulated by the administration of toci-
lizumab in patients with NSTEMI, particularly in the 
context of PCI, and that could potentially be second-
ary downstream mediators of the beneficial effect of 
tocilizumab in this cohort. The findings with regard to 
PRTN3 and CCL23 are particularly noteworthy and 
warrant further investigation. As the interest in targeting 
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the consequence of this approach in detail may lead 
to the identification of new targets and more effective 
therapeutics.
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Table S1. Antibodies used for EIA.
Protein Supplier Antibody Capture Antibody Detection 
Lipopolysaccharide-binding protein R&D systems Mouse, monoclonal Goat, polyclonal 
C-C motif chemokine ligand 23 R&D systems Mouse, monoclonal Goat, polyclonal 
Hepcidin  R&D systems Rabbit, monoclonal Rabbit, monoclonal 
Insulin like growth factor binding protein 4 R&D systems Mouse, monoclonal Goat, polyclonal 
Vascular endothelial growth factor A R&D systems Mouse, monoclonal Goat, polyclonal 
Myeloblastin/PRTN3 R&D systems Mouse, monoclonal Mouse, monoclonal 




 http://ahajournals.org by on February 2, 2021
Table S2. All proteins identified by the SOMAscan assay with a p-value of <0.05.
Protein (SOMAscan name) 
Log Mean diff TCZ-
placebo SE p value 
Interleukin-6 receptor subunit alpha 1.25 0.08 2.31E-20 
Alpha-1-antichymotrypsin complex 0.36 0.06 3.25E-07 
Hepcidin -0.68 0.13 2.41E-06 
Insulin-like growth factor-binding protein 4 -0.22 0.05 2.71E-05 
Myeloblastin 0.65 0.14 3.76E-05 
Vascular endothelial growth factor A -0.20 0.04 4.13E-05 
Interleukin-6 0.81 0.18 4.82E-05 
Ck-beta-8-1 -0.36 0.08 5.00E-05 
C-C motif chemokine 23 -0.28 0.07 0.000262 
C5a anaphylatoxin -0.29 0.07 0.000376 
Lipopolysaccharide-binding protein -0.23 0.06 0.000561 
C-type lectin domain family 4 member M -0.11 0.03 0.001810 
Mitogen-activated protein kinase 14 0.25 0.08 0.001927 
Azurocidin 0.20 0.06 0.002362 
Protein S100-A9 -0.22 0.07 0.003216 
Kin of IRRE-like protein 3 0.19 0.06 0.003261 
Growth arrest-specific protein 1 -0.12 0.04 0.003322 
Complement decay-accelerating factor -0.14 0.05 0.003765 
Macrophage colony-stimulating factor 1 receptor 0.25 0.08 0.005122 
Tyrosine-protein kinase JAK2 -0.15 0.05 0.006712 
C-C motif chemokine 4-like 0.27 0.10 0.008218 
Serum amyloid P-component -0.12 0.04 0.008226 
Glucose-6-phosphate isomerase 0.37 0.14 0.009625 
Interleukin-17F -0.19 0.07 0.009714 
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Immunoglobulin gamma Fc region receptor III-B 0.24 0.09 0.010483 
Cerebral dopamine neurotrophic factor -0.21 0.08 0.010806 
Myeloperoxidase 0.26 0.10 0.011464 
Tumor necrosis factor receptor superfamily member 1A -0.18 0.07 0.011650 
Cystatin-S -0.25 0.10 0.015080 
Somatostatin-28 -0.13 0.05 0.017296 
Bone morphogenetic protein receptor type-1A -0.16 0.07 0.020002 
Interleukin-16 0.20 0.08 0.020767 
Interleukin-8 0.18 0.08 0.022531 
Copine-1 0.33 0.14 0.022640 
beta-adrenergic receptor kinase 1 0.41 0.18 0.023288 
Inter-alpha-trypsin inhibitor heavy chain H4 -0.09 0.04 0.023431 
Hemojuvelin -0.17 0.07 0.023521 
Dynactin subunit 2 -0.11 0.05 0.024462 
Transforming growth factor beta receptor type 3 -0.13 0.06 0.026103 
Ephrin-A4 -0.14 0.06 0.026112 
C-X-C motif chemokine 16 -0.11 0.05 0.028414 
Dual specificity mitogen-activated protein kinase kinase 4 -0.20 0.09 0.029091 
Erythropoietin -0.25 0.11 0.029717 
Moesin -0.25 0.11 0.030028 
Cardiotrophin-like cytokine factor 1 Complex 0.20 0.09 0.032515 
L-lactate dehydrogenase B chain 0.24 0.11 0.034243 
Lymphotoxin alpha1:beta2 0.11 0.05 0.036623 
Platelet-derived growth factor receptor beta -0.28 0.13 0.036766 
Cyclin-dependent kinase 2:Cyclin-A2 complex 0.20 0.10 0.039800 
Fibroblast growth factor 18 0.42 0.20 0.040492 
Tropomyosin beta chain -0.15 0.07 0.041355 
Proteasome subunit alpha type-1 0.10 0.05 0.044684 
Complement component C6 -0.08 0.04 0.044729 
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Protein FAM107A -0.16 0.08 0.045972 
Fibroblast growth factor 8 isoform A 0.20 0.10 0.046155 
C-C motif chemokine 24 0.25 0.12 0.046868 
Calcium/calmodulin-dependent protein kinase type 1 -0.19 0.09 0.047212 
Desert hedgehog protein N-product 0.20 0.10 0.049036 
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Table S3. Proteins associated with the enriched GO term ‘cell chemotaxis’.




C-C motif chemokine ligand 23 (CCL23) Reduced Chemokine 
LPS binding protein (LBP) Reduced Acute Phase Protein 
Complement C5 (C5) Reduced Complement 
S100 calcium binding protein A9 (S100A9) Reduced Calcium-binding protein 
Platelet derived growth factor receptor beta (PDGFRB) Reduced Growth factor 
Vascular Endothelial Growth factor A (VEGFA) Reduced Growth Factor 
Interleukin 37 (IL37) Reduced Cytokine 
C-X-C motif chemokine ligand 16 (CXCL16) Reduced Chemokine 
Fibroblast growth factor 18 (FGF18) Elevated Growth Factor 
Azurocidin 1 (AZU1) Elevated Serine Protease 
C-C motif chemokine ligand 24 (CCL24) Elevated Chemokine 
C-X-C motif chemokine ligand 8 (CXCL8) Elevated Chemokine 
C-C motif chemokine ligand 4 like 1 (CCL4L1) Elevated Chemokine 
Mitogen-activated protein kinase 14 (MAPK14) Elevated Kinase 
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Figure S1. Selection of SOMAscan data transformation method. Proteomic
transformations assessing the distribution of the a) proportion of outliers b) skewness and c) 
kurtosis. This was performed with data from all proteins in the 1.3k SOMAscan assay 
(before proteins removed in the quality-control process). The X axis refers to the 1.3k 
SOMAscan proteins. The Y axis denotes, from top to bottom to the proportion of outliers, 
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